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PDB3
Regional assessment of seveRe HyPoglycemic coma events in 
finlanD
Vattulainen P.1, Mushnikov V.1, Hoti F.1, Saukkonen T.2, Korhonen P.1
1EPID Research, Espoo, Finland,, 2Novo Nordisk Farma, Espoo, Finland
Objectives: In a previous study about severe hypoglycemic coma events (SH) 
among diabetes mellitus (DM) patients we saw regional variation in SH occurrence. 
The purpose was to compare the incidence of SH between hospital districts in 
Finland. MethOds: This study among type 1 (T1) and 2 (T2) diabetic patients was 
based on nationwide health care registers. The study cohort contained insulin naïve 
diabetic patients who had filled at least one prescription of insulin during follow-up 
in 2006-2009. SH was defined as a hospitalization or a secondary health care visit 
due to hypoglycemic coma (ICD-10: E10.00 and E11.00). Stratified incidence rates and 
adjusted hazard ratio (HR) estimates with 95% confidence intervals (CI) were calcu-
lated. Analyses were performed for the first and recurrent SHs. Results: The popu-
lation comprised 5271 (17.6%) patients with T1 and 24602 (82.4%) with T2. Altogether 
3.1% patients experienced at least one SH during the follow-up. In different hospital 
districts the rate of first SHs varied from 5.6 (Varsinais-Suomi) to 47.8 (Länsi-Pohja) 
for T1, and from 4.8 (Pohjois-Karjala) to 50.3 (Länsi-Pohja) for T2. Compared to the 
capital area, the risks of first SHs varied differently for T1 and T2, but were com-
monly higher in Länsi-Pohja (T1: HR 3.46, CI 1.41-8.46; T2: HR 1.60, CI 1.13-2.29) and 
lower in Pohjois-Karjala (T1: no events; T2: HR 0.275, CI 0.14-0.56). Taking all SH 
events into account did not change these differences remarkably. cOnclusiOns: 
We found differences between regions in risk of hospital-treated SH in both DM 
types. Further analyses will be performed for e. g. ambulance density.
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HiPos-eR (HyPoglycemia in PoRtugal oBseRvational stuDy – 
emeRgency Room): clinical outcomes in aDmitteD Patients
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A.M.1
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Objectives: HIPOS-ER is an observational, cross-sectional, multicenter study to 
describe the patient population of Type 2 diabetics treated with an anti-hypergly-
cemic agent (AHA) and admitted to the emergency room (ER) with a hypoglycemic 
event. This is the first national hypoglycemia study in Portugal and the first study 
collecting hypoglycemia specific resource data directly in this setting. Here we aim 
to describe the clinical features of hospitalized patients. MethOds: The study 
enrolled patients from 7 centers in mainland Portugal for a period of 12 months 
(Jan 2013 – Jan 2014). Sociodemographic and clinical data were collected at the 
emergency room and patients who required hospital admission were followed up. 
Episodes were enrolled consecutively within the sampling period. Results: A total 
of 238 patients were enrolled, and 105 (44%) were hospitalized and 2 (1%) were 
transferred outside the hospital center for likely need of hospitalization. Mean age 
was 78 years, average disease duration was 19 years, 51% were female, 36% were 
on insulin, 51% on a secretagogue, 9% on an oral AHA excluding secretagogue and 
5% on insulin+secretagogue. 26% had complications diagnosed in the ER: Trauma 
(37%) and Cardiovascular (22%) and Infection/Sepsis (22%) were the most frequent. 
Mean and median hospitalization time was 9 and 5 days, respectively. Most (95%) 
patients were admitted to a medical department: Internal medicine (80%) and the ER 
observation/short stay unit (15%) were the most frequent. 6% of patients were admit-
ted to an intensive care unit. 8% (9) of hospitalized patients died. cOnclusiOns: 
Hospitalized diabetic patients following an ER episode due to hypoglycemia were 
treated mainly with secretagogue type drugs. Internal medicine was key in the 
hospital approach of these patients. The length of stay exceeded the 48-72h typical 
surveillance period for secretagogue-induced hypoglycemia. Severe hypoglycemia 
in Portugal is associated with several complications which also include death.
PDB5
comPaRative efficacy anD safety of emPagliflozin witH otHeR  
anti-DiaBetic DRugs foR tHe tReatment of Patients witH tyPe 2 
DiaBetes mellitus wHo aRe failing insulin
Thorlund K.1, Siliman G.1, Eapen S.1, Lund S.2, Palencia R.3
1Redwood Outcomes, Vancouver, BC, Canada, 2Boehringer Ingelheim Pharma GmbH & Co. KG, 
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Objectives: The aim of the present network meta-analysis is to compare the effi-
cacy and safety of empagliflozin versus other anti-diabetic drugs, in patients with 
type 2 diabetes mellitus (T2DM) who are inadequately controlled with any insulin 
treatment and with or without other anti-diabetic drugs (ADs). MethOds: We 
performed a systematic review of randomized controlled trials (RCTs) and Bayesian 
network meta-analysis to establish the comparative efficacy and safety of SGLT-2s, 
DPP-4s, GLP-1s and TZDs in T2DM patients. The principal outcome of this analysis 
was the effect of these drugs on HbA1c, weight, systolic blood pressure (SBP), inci-
dence of hypoglycaemia and urinary tract infections (UTIs) at 24 weeks. Results: 
Sixteen RCTs were included. All patients received insulin treatment (any type) with 
or without other additional ADs. Compared with placebo, mean changes in HbA1c 
were -0.51 % [95% confidence interval (CI) -0.93 to -0.11%] and -0.60% [95%CI -1.03 to 
-0.19%] for empagliflozin 10mg and 25mg, respectively. HbA1c reduction was similar 
for all other interventions, and no significant differences were detected. Compared 
with placebo, Empagliflozin 10mg and 25mg significantly reduced patients weight by 
approximately -1.5kg. Other SLGT-2s and all GLP-1s were associated with a similar 
weight loss, not change was observed for DPP-4s, and non-significant weight gains 
were observed for TZDs. Empagliflozin was also associated with significant reduc-
tions in SBP, and no significant differences between treatments were detected. For 
hypoglycaemic events, empagliflozin 10mg and 25mg were associated with non-
significant relative risks of 1.03 and 1.23. All interventions had non-significant rela-
tive risks of UTIs. cOnclusiOns: Compared with other treatments, empagliflozin 
comparison, and health economic examples. In the numerical comparison, the 
valuations of all 243 different EQ-5D states and all pure improvements were com-
pared. In the empirical study, a database of 23,925 individuals was used to identify 
patient groups that could be influenced by the implementation of experience-based 
value sets. Two hypothetical health economic examples were used to examine the 
implication of the choice of value set for decision makers. Results: The numeri-
cal comparison showed that only three health states were assigned a lower QALY-
weight in the experience-based value set. The empirical comparison showed that 
severe conditions were assigned higher values in case of experience-based value set. 
Furthermore, the health economic examples showed the choice of a value set has an 
effect on the health economic result. cOnclusiOns: Shifting to experience-based 
QALY-weights would increase the estimated level of quality of life in virtually all 
health conditions. In extension, quality of life enhancing interventions are given 
higher priority in decision making situations where hypothetical values are used to 
construct QALY-weights. On the other hand, in situations where experience-based 
QALY-weights are used, life-prolonging interventions will be prioritised.
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Objectives: HIPOS-ER is an observational study to describe the patient population of 
Type 2 Diabetics treated with an anti-hyperglycemic agent (AHA) and admitted to the 
emergency room (ER) with a hypoglycemic event. In this analysis we aim to describe 
the hypoglycemia events by AHA class. MethOds: The study enrolled patients from 7 
centers in mainland Portugal from Jan 2013 – Jan 2014. Sociodemographic and clinical 
data were collected at the emergency room and patients who required hospital admis-
sion were followed up. Episodes were enrolled consecutively within the sampling 
period. AHA therapy classes were Insulin - Group 1, secretagogue based - Group 2, oral 
AHA excluding secretagogue - Group 3 and Insulin+secretagogue – Group 4. Results: 
A total of 238 patients were admitted to the ER with severe hypoglycemia and 105 
(44%) were hospitalized. The distribution based on AHA therapy: 55% (131) Group 1, 
32% (75) Group 2, 7% (16) Group 3 and 7% (16) Group 4. Previous severe hypoglycemia 
in the last 12 months was more frequent in Group 1 vs. Group 2 (p= 0.009). Group 
2 patients were more often followed up in Primary Care vs. Group 1 (84% vs. 48%; 
p< 0.001) and Group 4 (44%, p= 0.002). Group 2 patients were more often hospitalized vs. 
Group 1 (71% vs. 29%; p< 0.001) and Group 4 (31%; p= 0.003). There was no difference in 
terms of the length of stay or hospitalization outcome. 9 deaths occurred: 5 in Group 
1, 3 in Group 2 and 1 in Group 3. cOnclusiOns: In the first national study on severe 
hypoglycemia in Type 2 diabetics, patients treated with Group 2 drugs were followed 
mainly in Primary care setting. More patients on Group 2 drugs were hospitalized. 
Within our sample there is little clinical difference in the hypoglycemia events with 
different therapys besides the need for hospitalization.
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Wales, PA, USA, 6Merck & Co., Inc., Whitehouse Station, NJ, USA
Objectives: HIPOS-ER is an observational, cross-sectional, multicenter study to 
characterize the population of Type 2 Diabetics treated with an anti-hyperglycemic 
agent (AHA) who were admitted to the emergency room (ER) with a hypoglycemic 
event. This is the first national ER hypoglycemia study and the first study collecting 
primary resource data in this setting. Here we aim to describe this population and 
the hospital management. MethOds: The study enrolled patients from 7 centers 
in mainland Portugal from Jan 2013 – Jan 2014. Sociodemographic and clinical data 
were collected within the emergency room and patients who required hospital 
admission were followed-up. Results: A total of 238 events were recorded. Mean 
age: 76 years; average disease duration: 19 years; 58% female; 80.9% were not 
living alone; 83% no formal education or schooling < 4 years; 25% had a previous 
episode of severe hypoglycemia in the preceding 12 months and 61% were treated 
in a primary care setting. Regarding drug treatment: 55% on insulin; 32% on a 
secretagogue; 7% on other oral AHA and 7% on insulin+secretagogue. Missing a 
meal was the most frequent immediate cause of hypoglycemia (56%). All patients 
received lab evaluations. 71% underwent radiological procedures. Time spent in 
the ER was 11 hours (mean) and the average medical and nurse time utilized was 
85 and 71 min respectively. AHA therapy was changed in 65% of cases: insulin 
adjustment (56%) being the most frequent modification. 56% (132) of patients were 
discharged. cOnclusiOns: Diabetic patients admitted to the ER have several 
markers of frailty and low educational status. Strategies to mitigate hypoglycemia 
underline the need to avoid missed meals. ER episodes are lengthy and consume 
significant physician and nurse time as well as laboratory and other diagnostic 
procedures. Primary care stakeholders should be involved in actions to mitigate 
hypoglycemia in type 2 diabetes.
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26 years period was associated with 18,59 LYG. At the same time use of autocoded 
blood glucose meters was associated with 18,92 LYG. In case of using autocoded 
meters instead of using manually coding meters patients obtained 0,33 LYG more 
(120 days). cOnclusiOns: Obtained results showed that difference in glucose 
measurement errors between manually coded and autocoded blood glucose meters 
can lead to the difference in long-term outcomes in diabetes treatment.
PDB9
assessing tHe RelationsHiP Between imPRoveD life exPectancy 
Due to BetteR caRDiovasculaR Risk factoR management anD tHe 
likeliHooD of micRovasculaR comPlications in tyPe 2 DiaBetes 
mellitus
McEwan P.1, Grant D.2, Foos V.3
1Health Economics and Outcomes Research Ltd, Cardiff, UK, 2IMS Health, London, UK, 3IMS 
Health, Basel, Switzerland
Objectives: Type 2 diabetes mellitus (T2DM) is a chronic disease associated 
with increased risk of cardiovascular (CV) and microvascular complications. 
Improvements in blood pressure and cholesterol control have resulted in a reduc-
tion in CV event rates in clinical practice. The objective of this study was to assess 
the relationship between increased life expectancy, due to reduction in CV event 
rates, and the risk of microvascular disease for a range of glycemic control lev-
els. MethOds: A lifetime analysis was conducted using the CORE diabetes model 
(CDM). Newly diagnosed T2DM simulated patients aged 52 years at baseline with 
HbA1c 7.1%, SBP 135.1 mmHg, total cholesterol: HDL 5.2 mmol/l were modelled. The 
impact of HbA1c on microvascular complications was assessed by running the CDM 
with baseline HbA1c ±1% for scenario 1: 100% of patient receiving CV risk factor 
management; and scenario 2: no CV risk factor management. Results: Improved 
CV risk factor management reduced the predicted cumulative incidence of fatal 
myocardial infarction (MI) from 27% to 18%, increasing life expectancy by an aver-
age of 2 years. For scenario 1, baseline HbA1c +1% versus -1% was associated with 
a 20%, 11% and 4% increase in microalbuminuria (MA), gross proteinuria (GRP) and 
end stage renal disease (ESRD), respectively; for scenario 2, the increase was 15.5% 
for MA, 7.6% for GRP and 2.5% for ESRD. Cumulative incidence of neuropathy ranged 
from 68.4% (baseline HbA1c +1%) to 42.1% (baseline HbA1c -1%) for scenario 1 and 
from 65.2% (baseline HbA1c +1%) to 39.7% (baseline HbA1 c-1%) for scenario 2. 
Cumulative retinopathy rates were similar across both scenarios: 56.7% versus 56.0% 
for scenarios 1 and 2, respectively. cOnclusiOns: This modeling study suggests 
that improvements in blood pressure and cholesterol management may result in 
increased rates of microvascular complications, in particular renal disease, over the 
long term as patient survival increases.
PDB11
a systematic Review anD netwoRk meta-analysis assessing tHe 
effectiveness anD toleRaBility of gliPtins anD sulfonyluReas as 
monotHeRaPy in Patients witH tyPe 2 DiaBetes mellitus if metfoRmin 
is not consiDeReD aPPRoPRiate
Bartmus T., Mansmann U.
Institut für medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-
Maximilians-Universität, Munich, Germany
Objectives: A significant proportion of patients with type-2-diabetes mellitus 
(T2DM) are unable to take Metformin as recommended first-line therapy due to 
gastrointestinal intolerance or contraindications such as chronic kidney disease. 
In contrast to combination therapy no network meta-analysis (NMA) has been 
undertaken for oral anti-diabetic drugs (OAD) as monotherapy in this population - 
particularly with respect to gliptins and sulfonylureas as second-line options. The 
purpose of this study is to assess the comparative effectiveness and tolerability of 
gliptins versus sulfonylureas in terms of glycated hemoglobin (HbA1c), body weight 
and hypoglycemia. MethOds: A systematic review was conducted searching bib-
liographic databases, reports of regulatory authorities and clinical trial registries 
through July 2012 to identify randomized controlled trials in adult T2DM patients 
receiving at least 12 weeks of OAD monotherapy or placebo. A Bayesian NMA was 
performed to yield mixed treatment comparisons. Consistency was examined by the 
node split method. Results: A total of 62 studies enrolling 21,302 patients informed 
the entire network. Due to their improved model fit estimates from random effect 
models are reported to account for heterogeneity across the set of studies. After a 
mean follow-up of 32 weeks, the difference in mean HbA1c was 0.26, 0. 95 credible 
interval (CrI0.95): [0.1; 0.42], in favour of sulfonylureas. However, gliptins induced 
weight loss (difference in means: -1.21 kg; CrI0.95: [-1.57; -0.84] ) and were associated 
with a considerably lower incidence of any hypoglycemia compared to sulfonylureas 
(odds ratio: 0.22; CrI0.95: [0.15; 0.31] ). All effect estimates were statistically significant 
and consistent in terms of combining direct and indirect evidence. cOnclusiOns: 
This is the first network assessing OAD monotherapy that can readily be extended 
to emerging therapies. With regard to glycemic control gliptins were slightly inferior 
to sulfonylureas, whereas they positively affected body weight and risk of hypogly-
cemia, confirming their role in second-line monotherapy.
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glycemic, liPiD, anD BlooD PRessuRe contRol among inDiviDuals 
witH tyPe 2 DiaBetes mellitus in sauDi aRaBia
Osenenko K.M.1, Szabo S.M.1, Donato B.M.K.2, Korol E.E.1, Qatami L.3, Al Jaser S.4, Al Saggabi A.4, 
El Seid M.E.4, Maclean R.5, Levy A.R.1
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Objectives: Inadequate glycemic, blood pressure (BP), and low-density lipopro-
tein (LDL) control among persons with type 2 diabetes mellitus (T2DM) increases 
the risk of T2DM-related complications, which require more intensive and costly 
therapy. Extending on a recently-conducted study in Dubai, UAE, we assessed levels 
of glycemic, LDL, and BP control, and estimated the proportion of those meeting 
offers similar or reduced HbA1c reduction, had comparable significant weight loss 
to other SLGT-2s and GLP-1s, and appeared to have a superior weight loss profile 
compared with DPP-4s and TZDs.. No increased risk of adverse events were observed 
for empagliflozin compared with placebo and other ADs.
PDB6
comPaRative efficacy anD safety of emPagliflozin witH otHeR 
antiDiaBetic DRugs foR tHe tHiRD line tReatment of tyPe 2 DiaBetes 
mellitus
Thorlund K.1, Siliman G.1, Eapen S.1, Lund S.2, Palencia R.3
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Ingelheim am Rhein, Germany, 3Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany
Objectives: The aim of the present network meta-analysis is to compare the effi-
cacy and safety of empagliflozin versus other antidiabetic drugs used in third line 
for the treatment of patients with type 2 diabetes mellitus (T2DM). MethOds: We 
conducted a systematic review randomized controlled trials (RCTs) and Bayesian 
network meta-analysis to establish the comparative efficacy and safety of SGLT-2s, 
DPP-4s, GLP-1s, and TZDs. RCTs enrolling subjects with T2DM inadequately con-
trolled on metformin plus sulfonylurea were included. The principal outcome of 
this analysis was the effect of these drugs on HbA1c, weight, systolic blood pres-
sure (SBP), incidence of hypoglycaemia and urinary tract infections (UTIs) at 24 
weeks. Results: From 6969 abstracts, 13 were included in the analysis. No RCTs 
involving TZDs were identified. Compared with placebo, mean changes in HbA1c 
were -0.65% [95% confidence interval (CI) -1.59 to -0.08%] and -0.60% [95%CI -1.14 to 
-0.14%] for empagliflozin 10mg and 25mg. No significant differences were detected 
between interventions. Mean changes in weight with empagliflozin 10mg and 25mg 
were -1.77 [95%CI -2.19 to -1.35) and -2.00 (95%CI -2.44 to -1.57), respectively. Mean 
weight losses were fairly similar across SLGT-2s and GLP-1s ranging between -1.26 
to -2.12. All DPP-4s were associated weight gains, ranging form 0.33 to 0.98, of which 
most were statistically significant. SBP data were only available for SGLT-2s and 
DPP-4s. Empagliflozin 10mg and 25mg compared with placebo had statistically sig-
nificant reductions of -2.70 and -2.09. All interventions (except exenatide) yielded 
relative risk of hypoglycaemia greater than 1.00. For UTIs, no differences were found 
between SLGT-2s or DPP-4s and placebo. cOnclusiOns: Compared with other 
SGLT-2s, DPP-4s, and GLP-1s, empagliflozin generally offers similar HbA1c control 
at week 24, an advantageous profile in weight loss and reduction of SBP, as well as 
similar safety profile.
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Objectives: To compare the efficacy and safety of empagliflozin versus other sec-
ond-line treatment for patients with type 2 diabetes mellitus (T2DM). MethOds: A 
systematic review and Bayesian network meta-analysis were performed to identify 
randomized controlled trials (RCTs) assessing the efficacy and safety of SGLT-2s, 
DPP-4s, GLP-1s, TZDs, and SUs in patients with T2DM. RCTs enrolling subjects with 
T2DM inadequately controlled with metformin monotherapy were included. The 
principal outcomes were HbA1c, weight, systolic blood pressure (SBP), hypoglycae-
mia, and urinary tract infections (UTIs) at 24 weeks. Results: Forty-eight RCTs 
were included. The mean differences (MD) in HbA1c were -0.56% [95% confidence 
interval (CI) -1.06% to -0.08%] and -0.64% [95%CI -1.14 to -0.14%] for Empagliflozin 
10mg and 25mg vs placebo. All other interventions yielded similar reductions and 
no significant differences were detected between interventions. Empagliflozin 10mg 
and 25mg significantly changed patients’ weight by -1.63kg (95%CI -2.66 to -0.64) 
and -2.01kg (95%CI -3.02 to -1.02), versus placebo. Other SLGT-2s had similar MDs, all 
DPP-4s had no change, and GLP-1s fell in between. All SUs and TZDs were associated 
with significant weight gain versus placebo. For SBP, the MDs for Empagliflozin 10mg 
and 25mg versus placebo were -4.09mmHg (95%CI -6.97 to -1.18) and -4.81mmHg 
(95%CI -7.69 to -2.00). No significant differences between Empagliflozin and other 
interventions were detected. Incidence of hypoglycaemia for empagliflozin 10 and 
25 mg relative to placebo was 2.71 [95%CI 0.46 to 11.44] and 1.97 [95%CI 0.23 to 9.57], 
respectively. No significant differences were detected between emplagliflozin and 
other interventions. For UTIs, all yielded relative risks close to 1.00 when compared 
with placebo. cOnclusiOns: Compared with other SGLT-2s, DPP-4s, GLP-1s, TZDs, 
and SUs, empagliflozin offers similar HbA1c control at 24 weeks, a marked reduc-
tion in weight compared with DPP-4s, TZDs, and SUs, and a similar safety profile 
as other interventions.
PDB8
long-teRm moDeling of using manually coDeD anD autocoDeD 
BlooD glucose meteRs in DiaBetes tReatment
Yagudina R., Kulikov A., Babiy V.
I. M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: To obtain long-term clinical outcomes of using manually coded 
and autocoded blood glucose meters in diabetes treatment in the Russian 
Federation. MethOds: The model used in this study analyzed the influence of 
errors in blood glucose measurements (due to using manually or autocoded glu-
cose meters) on the treatment of patients with Type 1 and Type 2 diabetes during 
the 26 years period (the life-time period). Life years gained (LYG) was chosen as an 
outcome measure in assessment of health intervention. Calculation of LYG was 
based on prior clinical studies that evaluated glucose meters’ errors in glucose 
level measurements and risk of complications associated with blood glucose level. 
Data for patients with diabetes was obtained from prior epidemiological studies 
that had been provided in Russian Federation. Results: Use of manually coded 
blood glucose meters in the analyzed population with median age of 53 years during 
